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Introduction
Combination antiretroviral therapy (cART) has transformed the outcome of human immunodefi-
ciency virus-1 (HIV-1) infection from a severe immunodeficiency syndrome to a chronic clinically
manageable disease. However, patients require lifelong therapy and are at risk of developing non-
AIDS complications (1, 2). Despite viral suppression in patients on cART, HIV-1 persists via the
establishment of a latent reservoir. The adverse aspects and burden of lifelong cART together with
the establishment of HIV-1 latency substantiate the need for an HIV-1 cure. A cure will either
require complete eradication of the latent HIV-1 reservoir (termed “sterilizing cure”), or a sufficient
reduction of HIV-1 levels wherein long-term viral suppression can be achieved without cART
(termed “functional cure”). A key barrier to an HIV-1 cure is the persistence of latent replication-
competent HIV-1 within long-lived resting CD4+ T cells (3). Without active HIV-1 replication or
antigen expression, these latently infected cells are hidden from cART and are not eliminated by
immune responses.
HIV-1 Cure Strategies
The Berlin patient is widely regarded as a proof-of-concept for an HIV-1 cure (4–6). The patient
received a bone marrow transplant from a donor with the homozygous CCR5 ∆32 mutation,
which confers high resistance to most strains of HIV-1 (7). Remarkably, viremia has remained
undetectable for 6 years in the absence of cART. Two additional patients (the “Boston patients”),
who received transplants from non-HIV-1-resistant donors, only had non-sustained remission
periods (3–8months) where HIV-1 viremia remained absent after cessation of cART before HIV-1
rebounded to high levels (8). Until very recently, early and intense cART intervention during acute
HIV-1 infection was postulated to be a feasible cure approach. The “Mississippi baby” was thought
cured of HIV-1 after receiving intense cART during acute HIV-1 infection (9). However, HIV-1
rebounded in the baby after 27months of viral remission in the absence of cART, implying that
HIV-1 latency was established early after infection and that latent cells can remain dormant for long
periods prior to becoming reactivated (10, 11).
An alternative method for eliminating the latent reservoir is the “shock and kill” approach where
latently infected cells are reactivated to express the HIV-1 genome (“shock”) and are subsequently
killed by the immune system or viral cytopathic effects (“kill”) (12). cART administered alongside
virus reactivation by latency-reversing agents (LRAs) should impede the infection of new cells.
Clinical studies are now beginning to understand how to disrupt the HIV-1 latent reservoir.
Several histone deacetylase inhibitors (HDACi) have been studied in vitro with promising results
(13). However, recently completed clinical trials examining the HDACi vorinostat, panobinostat,
and romidepsin as LRAs showed only partial success (14–16). Although these HDACi induced
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a significant and sustained increase in HIV-1 transcription
(mRNA) and/or plasma viremia from latency in the majority of
HIV-1-infected patients, they failed to decrease total integrated
HIV-1DNA– an indication that the viral reservoir did not change.
A more promising study showed that administration of a toll-
like receptor 7 agonist as an LRA to simian immunodeficiency
virus (SIV)-infected rhesus macaques treated with cART induced
transient plasma viremia and resulted in a decrease in total SIV
DNA levels (17).
Despite the large research effort investigating approaches to
reactivate HIV-1 expression in latently infected cells, there is
limited knowledge on the fate of these cells following reactivation.
Shan et al. demonstrated that latently infected cells derived from
HIV-1-infected subjects that were reactivated with the HDACi
vorinostat ex vivo did not die from viral cytopathic effects and
were not killed by autologous cytotoxic T lymphocytes (CTL),
which may have been relatively quiescent in the presence of cART
(18). The reactivated latently infected cells were, however, par-
tially killed by autologous CTLs that were pre-stimulated with
HIV-1 antigens. Consequently, there is a risk that the surviving
reactivated cells may revert back to latency and replenish the
latent reservoir. As such, HIV-1 reactivation from latency alone is
not sufficient to eliminate the latent reservoir. This suggests that
further immune modalities may need to be harnessed to purge
latently infected cells.While pre-stimulation of CTLs ex vivo could
lead to elimination of reactivated latently infected cells, protec-
tive CTL responses tend to be restricted by rather uncommon
HLA-I alleles (HLA-B27, HLA-B57) (19, 20). Also, a recent study
demonstrated that the majority of viruses in the latent reservoir
carry CTL escape mutations that render reactivated cells partially
resistant to elimination by immunodominant CTL responses (21).
Still, appropriate boosting of these CTL responses will most likely
be required for the elimination of the latent reservoir, which is
difficult with current HIV-1 therapeutic vaccine strategies that
have shown only modest success in vivo (22–24). Although there
may be vaccine strategies [such as cytomegalovirus vector vac-
cines (25)] that can induce CTLs to non-escaped, unusual and
diverse epitopes, thismay prove difficult. The efficacious potential
of non-CTL immune responses capable of eliminating the latent
reservoir needs to be explored.
Antibody-Dependent Cellular Cytotoxicity
Against HIV-1
We postulate that HIV-1-specific antibodies might be able to
mediate killing of reactivated latently infected cells through
antibody-dependent cellular cytotoxicity (ADCC). HIV-1-
specific ADCC involves the binding of antibodies to HIV-1
antigens expressed on the infected cell surface and the subsequent
recruitment of innate effector cells, such as natural killer (NK)
cells or monocytes (26). The cross-linking of Fcγ receptors on
these innate immune cells by the Fc region of IgG antibodies
results in the cytolysis of infected cells as well as the release of
cytokines and chemokines by the innate effector cells (26–28).
Numerous studies have suggested a protective role for ADCC
against HIV-1 infection. High levels of HIV-1-specific ADCC
antibodies have been correlated with slower disease progression
(29–31), and have been shown to play a role in controlling HIV-1
infection in elite controllers, a rare group of individuals able
to suppress viremia below detection limits without cART (32).
Furthermore, ADCC antibodies have been implicated as an
immune correlate in the moderately successful HIV-1 RV144
vaccine trial (33, 34).
Potential Barriers for ADCC-Mediated
Elimination of the Reactivated Latent
HIV-1 Reservoir
Although theoretically attractive, whether reactivated latently
infected cells can serve as targets for ADCC remains unclear. A
major determinant for ADCC responses against HIV-1-infected
cells is the availability of cell surfaceHIV-1 envelope (Env) protein
for the binding of ADCC antibodies. Even though results from
recent clinical trials of LRAs seem promising, it is not known
whether reactivated latently infected cells express sufficient Env
antigens on the surface for efficient binding of ADCC antibodies.
While the level of Env expressed on the surface is an important
factor for anti-HIV-1 ADCC, the conformation of Env and conse-
quent availability of epitopes for the binding of ADCC antibodies
might be even more critical. As reviewed in Kramski et al. (35),
several recent studies have shown that HIV-1-infected cells can
evadeADCC in vitro through the actions of the accessory proteins,
Vpu and Nef (36–38). Vpu and Nef can downregulate surface
CD4 expression, thereby preventing CD4–Env interactions on the
surface of infected cells. This leads to the concealment of many
ADCC antibody epitopes that are only exposed on CD4-bound
Env trimers, thus reducing the level of ADCC antibodies binding
to infected cells (38). Furthermore, a recent study reported that
the majority of anti-HIV-1 ADCC antibodies in sera from HIV-
1-infected individuals recognize CD4-induced epitopes on Env,
which are mostly concealed on HIV-1-infected cells (39). In addi-
tion,Vpu inhibits the host restriction factor tetherin, which tethers
nascent virions to the surface of infected cells. By doing so, Vpu
ensures the efficient release of virions and also reduces the level
of HIV-1 antigens available for ADCC antibody binding (36, 37).
Overall, sufficient HIV-1 antigen expression and epitope avail-
ability on reactivated cells through the use of potent LRAs, and
perhaps, the therapeutic inhibition of Vpu and Nef will be needed
to enhance ADCC antibody-binding to reactivated cells (40).
Another potential barrier for ADCC-mediated elimination of
the latent HIV-1 reservoir is that levels of HIV-1-specific ADCC
antibodies decline in HIV-1-infected individuals on long-term
cART (41). Similar to thewaning ofHIV-1-specific CTL responses
in patients on cART (42), the decline in HIV-1-specific ADCC
antibodies likely results from a lack of antigen stimulation as a
result of cART-mediated viral suppression. However, the decline
in ADCC antibodies is much less substantial than the decline in
CTL responses on cART. If ADCC antibodies are indeed capable
of eliminating reactivated latently infected cells, it is not known
whether the level of ADCC antibodies will need to be boosted
prior to latency reversal. Although antibody-inducing protein-
based HIV-1 vaccines may be more successful than CTL-based
vaccines, their efficacy in the context of HIV-1 cure strategies is
unknown. Therapeutic vaccines administered to HIV-1-infected
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individuals may also only expand pre-existing HIV-1-specific B
cells, which could have already induced viral escape from ADCC
in the earlier stages of infection (43), similar to that seen for CTLs
(21). Further activation of pre-existing B cell immunity toward
HIV-1 may also induce undesirable isotype switching, resulting
in a switch from ADCC-mediating isotypes (IgG) to non-ADCC-
competent isotypes (IgA) (34, 44). Thus, instead of attempting to
stimulate immune responses in HIV-1-infected individuals who
may have partially compromised immune systems, the passive
transfer of ADCC-mediating monoclonal antibodies might be a
more promising and easier approach.
Over the years, a series of potent and broadly neutralizing
Env-specific monoclonal antibodies (bNabs) have been isolated
from HIV-1-infected individuals (45–47). Many of these bNabs
have been shown to mediate ADCC as well. Barouch et al. and
Shingai et al. showed that the passive transfer of certain bNabs,
either individually or in combination, was able to induce suppres-
sion of viremia in macaques chronically infected with chimeric
simian-HIV (SHIV) (48, 49). Although not tested directly, the
demonstration by Barouch et al. (48) that these bNabs could
result in a reduction in proviral DNA suggests that ADCC against
SHIV-infected cellsmay have been important in reducing viremia.
Halper-Stromberg et al. demonstrated that administration of a
combination of bNabs followed by a combination of LRAs could
result in decreased viral rebound from HIV-1 latently infected
cells in a humanized mouse model of HIV-1 infection (50). These
results suggest that the passive transfer of ADCC-competent
antibodies to patients, along with LRAs, could result in ADCC-
mediated elimination of reactivated latently infected cells and
purge the latent reservoir. Similar to the use of multiple drugs
for cART, administration of a combination of multiple mono-
clonal antibodies is most likely to prevent emergence of viral
escape mutants. Since Env is likely to be in the native closed
trimeric conformation due to CD4-downregulation by Vpu and
Nef, and HIV-1-infected individuals predominantly have serum
ADCC antibodies that recognize CD4-induced epitopes on Env
(39), ADCC-competent monoclonal antibodies that bind to non-
CD4-dependent epitopes on Env are highly desirable. Future
studies need to assess whether (1) ADCC is a potential immune
mechanism to eliminate reactivated latently infected cells in vivo,
and (2) if native Env trimer-binding, ADCC-competent bNabs
can eliminate latently infected cells following administration
of LRAs.
Even if ADCC antibodies can efficiently recognize HIV-1-
infected cells, the demonstration that autologous CTLs from
patients on cART were unable to kill reactivated latently infected
cells without prior antigen stimulation raises concerns that NK
cells in these patients may not be able to eliminate the reacti-
vated reservoir either (18). While some studies have shown that
NK cells in HIV-1-infected patients remain capable of medi-
ating ADCC (51, 52), other studies demonstrate that the NK
cells may become “exhausted” and exhibit reduced functionality
due to chronic immune activation (53, 54). Exhausted NK cells
may express lower levels of CD16 (55), reduced levels of NK
cell activating receptors (53), and have impaired CD16 signaling
(54). Indeed, we have demonstrated that CD16-downregulation
is induced by activation of NK cells in an anti-HIV-1 antibody-
dependent manner (56, 57). This downregulation is mediated
by matrix metalloproteinases (MMPs) and inhibition of MMPs
can prevent CD16-downregulation or restore CD16 expression on
previously activated NK cells (55, 56) Thus, immune modulating
strategies including MMP inhibition, in vivo cytokine therapy, or
adoptive NK cell therapy may need to be implemented to boost
NK cell functionality before latency reversal to unleash the full
potential of ADCC antibodies in cure strategies.
Conclusion
Despite the increasing efforts funneled into HIV-1 cure research,
an HIV-1 cure still remains elusive. The relapse of the “Boston
patients” and the “Mississippi baby” after months of viral suppres-
sion emphasizes the difficulty of the task ahead. Recent studies
show the potential utility of CTL immune responses in clearing
reactivated latently infected cells. Moving forward, CTL function-
ality in cART-treated patientsmay need to be boosted anddirected
toward sub-dominant epitopes. In addition to CTL responses,
ADCC represents another immunemechanism and further inves-
tigation to assess its potential to clear reactivated latently infected
cells is warranted. Advances in HIV-1 cure strategies will require
an improved understanding of not only how to reactivate HIV-1
from latently infected cells, but also how to clear them with the
most effective immune responses.
References
1. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and
non-AIDS related morbidity. BMJ (2009) 338:a3172. doi:10.1136/bmj.a3172
2. Neuhaus J, Angus B, Kowalska JD, La Rosa A, Sampson J, Wentworth D, et al.
Risk of all-cause mortality associated with nonfatal AIDS and serious non-
AIDS events among adults infected with HIV. AIDS (2010) 24(5):697–706.
doi:10.1097/QAD.0b013e3283365356
3. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al.
Long-term follow-up studies confirm the stability of the latent reservoir for
HIV-1 in resting CD4+ T cells.Nat Med (2003) 9(6):727–8. doi:10.1038/nm880
4. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, et al.
Evidence for the cure ofHIV infection byCCR5Delta32/Delta32 stem cell trans-
plantation. Blood (2011) 117(10):2791–9. doi:10.1182/blood-2010-09-309591
5. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, et al. Long-
term control ofHIVbyCCR5Delta32/Delta32 stem-cell transplantation.NEngl
J Med (2009) 360(7):692–8. doi:10.1056/NEJMoa0802905
6. HutterG, Thiel E. Allogeneic transplantation of CCR5-deficient progenitor cells
in a patient withHIV infection: an update after 3 years and the search for patient
no. 2. AIDS (2011) 25(2):273–4. doi:10.1097/QAD.0b013e328340fe28
7. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al.
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles
of the CCR-5 chemokine receptor gene.Nature (1996) 382(6593):722–5. doi:10.
1038/382722a0
8. Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, et al.
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem
cell transplantation: report of 2 cases. Ann Intern Med (2014) 161(5):319–27.
doi:10.7326/M14-1027
9. Persaud D, Gay H, Ziemniak C, Chen YH, PiatakM Jr, Chun TW, et al. Absence
of detectable HIV-1 viremia after treatment cessation in an infant.N Engl J Med
(2013) 369(19):1828–35. doi:10.1056/NEJMoa1302976
10. Luzuriaga K, Gay H, Ziemniak C, Sanborn KB, Somasundaran M, Rainwater-
Lovett K, et al. Viremic relapse after HIV-1 remission in a perinatally infected
child. N Engl J Med (2015) 372(8):786–8. doi:10.1056/NEJMc1413931
Frontiers in Immunology | www.frontiersin.org May 2015 | Volume 6 | Article 2653
Lee et al. ADCC in HIV cure
11. Siliciano JD, Siliciano RF. AIDS/HIV. Rekindled HIV infection. Science (2014)
345(6200):1005–6. doi:10.1126/science.1259452
12. Deeks SG. HIV: shock and kill. Nature (2012) 487(7408):439–40. doi:10.1038/
487439a
13. Wightman F, Ellenberg P, Churchill M, Lewin SR. HDAC inhibitors in HIV.
Immunol Cell Biol (2012) 90(1):47–54. doi:10.1038/icb.2011.95
14. Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, et al.
HIV-1 expressionwithin resting CD4+T cells aftermultiple doses of vorinostat.
J Infect Dis (2014) 210(5):728–35. doi:10.1093/infdis/jiu155
15. Rasmussen TA, TolstrupM, BrinkmannCR,Olesen R, ErikstrupC, SolomonA,
et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactiva-
tion in HIV-infected patients on suppressive antiretroviral therapy: a phase
1/2, single group, clinical trial. Lancet HIV (2014) 1(1):e13–21. doi:10.1016/
S2352-3018(14)70014-1
16. Søgaard OS, Graversen ME, Leth S, Brinkmann CR, Kjær AS, Olesen R,
et al. The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1
latency in vivo as measured by standard clinical assays. 20th International AIDS
Conference. Melbourne (2014).
17. Whitney J, Lim S-Y, Osuna C, Sanisetty S, Barnes T, Cihlar T, et al. Treatment
with a TLR7 agonist induces transient viremia in SIV-infected ART-suppressed
monkeys. 22nd Conference on Retroviruses and Opportunistic Infections. Seattle,
WA (2015).
18. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, et al. Stimulation
of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral
reservoir after virus reactivation. Immunity (2012) 36(3):491–501. doi:10.1016/
j.immuni.2012.01.014
19. Goulder PJ, Watkins DI. HIV and SIV CTL escape: implications for vaccine
design. Nat Rev Immunol (2004) 4(8):630–40. doi:10.1038/nri1417
20. Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN, et al. HLA
alleles associated with delayed progression to AIDS contribute strongly to the
initial CD8(+) T Cell Response against HIV-1. PLoS Med (2006) 3(10):e403.
doi:10.1371/journal.pmed.0030403
21. Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, et al. Broad
CTL response is required to clear latent HIV-1 due to dominance of escape
mutations. Nature (2015) 517(7534):381–5. doi:10.1038/nature14053
22. Autran B, Costagliola D,Murphy R, Katlama C. Evaluating therapeutic vaccines
in patients infected with HIV. Expert Rev Vaccines (2004) 3(4 Suppl):S169–77.
doi:10.1586/14760584.3.4.S169
23. Autran B, Kinloch-de Loes S, Katlama C. Therapeutic immunization in
HIV infection. Curr Opin HIV AIDS (2006) 1(4):323–9. doi:10.1097/01.COH.
0000232348.15909.c6
24. Garcia F, Leon A, Gatell JM, Plana M, Gallart T. Therapeutic vaccines against
HIV infection. Hum Vaccin Immunother (2012) 8(5):569–81. doi:10.4161/hv.
19555
25. Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz BJ, Scholz I, et al.
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms.
Science (2013) 340(6135):1237874. doi:10.1126/science.1237874
26. Kramski M, Parsons MS, Stratov I, Kent SJ. HIV-specific antibody immunity
mediated throughNKcells andmonocytes.CurrHIVRes (2013) 11(5):388–406.
doi:10.2174/1570162X113116660061
27. Daeron M. Fc receptor biology. Annu Rev Immunol (1997) 15:203–34. doi:10.
1146/annurev.immunol.15.1.203
28. Smalls-Mantey A, Connors M, Sattentau QJ. Comparative efficiency of HIV-1-
infected T cell killing by NK cells, monocytes and neutrophils. PLoS One (2013)
8(9):e74858. doi:10.1371/journal.pone.0074858
29. Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, et al. HIV-
1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with
rate of disease progression. J Immunol (1996) 157(5):2168–73.
30. Chung AW, Navis M, Isitman G, Wren L, Silvers J, Amin J, et al. Activation of
NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune
Defic Syndr (2011) 58(2):127–31. doi:10.1097/QAI.0b013e31822c62b9
31. Wren LH, Chung AW, Isitman G, Kelleher AD, Parsons MS, Amin J, et al.
Specific antibody-dependent cellular cytotoxicity responses associated with
slow progression of HIV infection. Immunology (2013) 138(2):116–23. doi:10.
1111/imm.12016
32. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, et al. Het-
erogeneous neutralizing antibody and antibody-dependent cell cytotoxicity
responses in HIV-1 elite controllers. AIDS (2009) 23(8):897–906. doi:10.1097/
QAD.0b013e328329f97d
33. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM,
et al. Immune-correlates analysis of anHIV-1 vaccine efficacy trial.NEngl JMed
(2012) 366(14):1275–86. doi:10.1056/NEJMoa1113425
34. Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, et al. Vaccine-
induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks
binding and effector function of IgG. Proc Natl Acad Sci U S A (2013)
110(22):9019–24. doi:10.1073/pnas.1301456110
35. Kramski M, Stratov I, Kent SJ. The role of HIV-specific antibody-dependent
cellular cytotoxicity in HIV prevention and the influence of the HIV-1 Vpu
protein. AIDS (2015) 29(2):137–44. doi:10.1097/QAD.0000000000000523
36. Arias JF, Heyer LN, von Bredow B, Weisgrau KL, Moldt B, Burton DR,
et al. Tetherin antagonism by Vpu protects HIV-infected cells from antibody-
dependent cell-mediated cytotoxicity. Proc Natl Acad Sci U S A (2014)
111(17):6425–30. doi:10.1073/pnas.1321507111
37. Alvarez RA, Hamlin RE, Monroe A, Moldt B, Hotta MT, Rodriguez Caprio G,
et al. HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular
cytotoxic responses by natural killer cells. J Virol (2014) 88(11):6031–46. doi:10.
1128/JVI.00449-14
38. Veillette M, Desormeaux A, Medjahed H, Gharsallah NE, Coutu M, Baalwa J,
et al. Interactionwith cellular CD4 exposesHIV-1 envelope epitopes targeted by
antibody-dependent cell-mediated cytotoxicity. J Virol (2014) 88(5):2633–44.
doi:10.1128/JVI.03230-13
39. Veillette M, Coutu M, Richard J, Batraville LA, Dagher O, Bernard N, et al.
The HIV-1 gp120 CD4-bound conformation is preferentially targeted by
antibody-dependent cellular cytotoxicity-mediating antibodies in sera from
HIV-1-infected individuals. J Virol (2015) 89(1):545–51. doi:10.1128/JVI.
02868-14
40. Bouchet J, Basmaciogullari SE, Chrobak P, Stolp B, Bouchard N, Fackler OT,
et al. Inhibition of the Nef regulatory protein of HIV-1 by a single-domain
antibody. Blood (2011) 117(13):3559–68. doi:10.1182/blood-2010-07-296749
41. Madhavi V, Ana-Sosa-Batiz FE, Jegaskanda S, Center RJ, Winnall WR, Parsons
MS, et al. Antibody-dependent effector functions against HIV decline in sub-
jects on antiretroviral therapy. J Infect Dis (2015) 211(4):529–38. doi:10.1093/
infdis/jiu486
42. Casazza JP, Betts MR, Picker LJ, Koup RA. Decay kinetics of human immun-
odeficiency virus-specific CD8+ T cells in peripheral blood after initiation of
highly active antiretroviral therapy. J Virol (2001) 75(14):6508–16. doi:10.1128/
JVI.75.14.6508-6516.2001
43. Chung AW, Isitman G, Navis M, Kramski M, Center RJ, Kent SJ, et al. Immune
escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC)
pressure. Proc Natl Acad Sci U S A (2011) 108(18):7505–10. doi:10.1073/pnas.
1016048108
44. Dugast AS, Stamatatos L, Tonelli A, Suscovich TJ, Licht AF, Mikell I, et al.
Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral anti-
body activity following acute infection. Eur J Immunol (2014) 44(10):2925–37.
doi:10.1002/eji.201344305
45. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, et al. Broad
neutralization coverage of HIV by multiple highly potent antibodies. Nature
(2011) 477(7365):466–70. doi:10.1038/nature10373
46. Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibod-
ies present new prospects to counter highly antigenically diverse viruses. Science
(2012) 337(6091):183–6. doi:10.1126/science.1225416
47. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC.
Antibodies in HIV-1 vaccine development and therapy. Science (2013)
341(6151):1199–204. doi:10.1126/science.1241144
48. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, et al. Thera-
peutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in
SHIV-infected rhesus monkeys. Nature (2013) 503(7475):224–8. doi:10.1038/
nature12744
49. Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, et al.
Antibody-mediated immunotherapy of macaques chronically infected with
SHIV suppresses viraemia. Nature (2013) 503(7475):277–80. doi:10.1038/
nature12746
50. Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L,
et al. Broadly neutralizing antibodies and viral inducers decrease rebound
from HIV-1 latent reservoirs in humanized mice. Cell (2014) 158(5):989–99.
doi:10.1016/j.cell.2014.07.043
51. Katz JD,Mitsuyasu R, GottliebMS, LebowLT, Bonavida B.Mechanism of defec-
tive NK cell activity in patients with acquired immunodeficiency syndrome
Frontiers in Immunology | www.frontiersin.org May 2015 | Volume 6 | Article 2654
Lee et al. ADCC in HIV cure
(AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular
cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK)
cytotoxicity. J Immunol (1987) 139(1):55–60.
52. Johansson SE, Rollman E, Chung AW, Center RJ, Hejdeman B, Stratov I, et al.
NK cell function and antibodies mediating ADCC in HIV-1-infected viremic
and controller patients. Viral Immunol (2011) 24(5):359–68. doi:10.1089/vim.
2011.0025
53. De Maria A, Fogli M, Costa P, Murdaca G, Puppo F, Mavilio D, et al. The
impaired NK cell cytolytic function in viremic HIV-1 infection is associated
with a reduced surface expression of natural cytotoxicity receptors (NKp46,
NKp30 and NKp44). Eur J Immunol (2003) 33(9):2410–8. doi:10.1002/eji.
200324141
54. Lichtfuss GF, ChengWJ, Farsakoglu Y, Paukovics G, Rajasuriar R, Velayudham
P, et al. Virologically suppressed HIV patients show activation of NK cells
and persistent innate immune activation. J Immunol (2012) 189(3):1491–9.
doi:10.4049/jimmunol.1200458
55. Liu Q, Sun Y, Rihn S, Nolting A, Tsoukas PN, Jost S, et al. Matrix metallopro-
tease inhibitors restore impairedNK cell-mediated antibody-dependent cellular
cytotoxicity in human immunodeficiency virus type 1 infection. J Virol (2009)
83(17):8705–12. doi:10.1128/JVI.02666-08
56. ParsonsMS, Tang CC, Jegaskanda S, Center RJ, Brooks AG, Stratov I, et al. Anti-
HIV antibody-dependent activation of NK cells impairs NKp46 expression.
J Immunol (2014) 192(1):308–15. doi:10.4049/jimmunol.1301247
57. Tang CC, Isitman G, Bruneau J, Tremblay C, Bernard NF, Kent SJ, et al.
Phenotypic and functional profiles ofNK cells exhibitingMMP-mediatedCD16
cleavage after anti-HIV antibody-dependent activation. Clin Exp Immunol
(2015). doi:10.1111/cei.12593
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Lee, Parsons, Kent and Lichtfuss. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org May 2015 | Volume 6 | Article 2655
